Sydney M Crago

The report details the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA).

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

The NHS is expanding the use of optical coherence tomography to enhance diabetic eye care, aiming to improve early detection of diabetic retinopathy and reduce the backlog of hospital appointments.

The program aims to expand access and affordability for Harrow's ophthalmic pharmaceutical products through targeted price reductions and a strategic partnership with GoodRx.

The CHMP has recommended FYB203 for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

After closing, the combined company is expected to operate under the name Kalaris Therapeutics, Inc.

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease who required frequent anti-VEGF injections before enrolling in the trial.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

Afqlir (aflibercept) is a 2 mg vial kit and pre-filled syringe for intravitreal injection.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).

Scientists at Scripps Research and its nonprofit drug development arm, the Calibr-Skaggs Institute for Innovative Medicines, are working to advance regenerative medicines capable of repairing tissues damaged by age-related disease

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in Chicago, Illinois, he stopped by the Eye Care Network booth to share insights from the symposium "Professional Longevity 2.0: Assessing the Ophthalmologist," which he presented during.

Valerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the on-call ophthalmologists. She shared these thoughts at this year's AAO meeting held in Chicago, Illinois.

Glenn C. Yiu, MD, PhD, from the University of California David, shared insights from his presentation on suprachoroidal drug delivery in the real world at this year's AAO meeting held in Chicago, Illinois.